Intero Biosystems

We are proud to be featured in the newest issue of the Colorado BioScience Association magazine! We relocated to Colorado in 2026 and are excited to be part of this vibrant ecosystem. We recommend reading the whole thing to learn about all of the amazing companies that are spotlighted, Intero is on page 12.

We are so excited to share that Intero WON TechCrunch Disrupt 2026 startup Battlefield 2026!! 🥳 🥇 It is an honor to follow in the footsteps of past winners like Glīd and Cellino. We met so many amazing companies who are truly changing the world across the Battlefield 200, Top 20, and Top 5. Thanks to Isabelle Johannessen and Michael J Schick for organizing such an amazing event! Learn more about how the competition finished here! https://lnkd.in/gJmswfGY

We have made it into the 2026 TechCrunch Startup Battlefield top five! 🏆 We will be pitching and demoing live on the Disrupt stage TODAY, Thursday, October 15, at 11:30 am pacific, competing for $100K and the Disrupt Cup along side 4 other amazing teams. If you’re at Disrupt, come see us pitch live! If you’re not, you can catch the livestream on TechCrunch.com and check out more about the teams and event here:

Surprise! 🎉 We’ve been selected as one of the Top 20 startups at TechCrunch Disrupt and will be pitching live on the Disrupt Stage tomorrow in Semifinal Session 3 Health Tech and Life Sciences (10:00am-11:15am Pacific). Tune in and cheer us on! 🚀 Check out the link in the comments to the press release on all the amazing companies competing!

Surprise! 🎉 We’ve been selected as one of the Top 20 startups at TechCrunch Disrupt and will be pitching live on the Disrupt Stage tomorrow in Semifinal Session 3 Health Tech and Life Sciences (10:00am-11:15am Pacific). Tune in and cheer us on! 🚀 Check out the link in the comments to the press release on all the amazing companies competing!

Welcome to the team, Sneha Iyer, M.S.! We’re excited to welcome Sneha to Intero Biosystems as an Associate Scientist. Sneha brings 5+ years of experience in stem cell biology, directed differentiation, organoids, disease modeling, and cell-based assay development. She has extensive experience developing and optimizing human stem cell-derived models, including cerebral organoids and neuronal models, with a strong focus on reproducibility and functional characterization. We’re thrilled to have her expertise on the team as we continue scaling our platform and advancing human-based models for research and drug development. Welcome to Intero, Sneha! 👩🔬

Welcome to the team, Sean McGrath Ph.D.! Our team is excited to welcome Sean to Intero Biosystems as a Principal Scientist - Manufacturing. Sean trained at Cincinnati Children’s Hospital, the epicenter of iPSC-derived human intestinal organoids, and brings deep expertise in stem cell biology, organoids, and human tissue modeling, along with years of experience leading organoid and tissue modeling research at the University of Colorado Anschutz Medical Campus. We’re thrilled to have his expertise on the team as we scale our platform and continue driving automation, scalability, and reproducibility in human-based testing. Welcome to Intero, Sean! 🧬

We are super excited to announce Intero Biosystems has been selected for this year's TechCrunch 2026 Startup Battlefield! Out of thousands of startups that apply across the globe each year, only 200 are selected and we’re incredibly excited to be among them. We’ll be showcasing the future of human-based testing and how our miniature human intestines can transform drug development, helping companies identify better therapies earlier and accelerate the path to the clinic. See all of the awesome startups who will be featured at the event and hope to see you there! Link in the comments.

Exciting news part 2! Intero Biosystems has been awarded a $350k Phase I SBIR from NIH NCATS to advance our human gut motility model. We're excited to continue developing more human-relevant tools for understanding how drugs, supplements, food ingredients, and other compounds affect the human gut before they ever reach patients. Another huge shoutout to our grant team Jason R. Spence, Madeline Eiken, PhD, and Sophia Meyer on another huge win this week. If you're interested in predicting human gut motility responses earlier in development, we'd love to connect!

Our team is excited to share that Intero Biosystems has been awarded $2M+ in Phase II SBIR funding from the National Institutes of Health's National Center for Advancing Translational Sciences (NCATS). The award supports continued development of GastroScreen, our multi-lineage, iPSC-derived human intestinal organoid platform for drug discovery and preclinical testing. This funding allows us to accelerate development of GastroScreen for our pharma and biotech partners who need better human-relevant models before the clinic. We are grateful to NCATS for the support, and to our fabulous grant writing team Sophia Meyer, Jason R. Spence and Madeline Eiken, PhD, for the work behind this milestone!